Having experienced psychosis herself, a psychologist wants us to rethink how we understand and treat this complex condition.
Conversations in Critical Psychiatry is an interview series that explores critical and philosophical perspectives in psychiatry and engages with prominent commentators within and outside the profession who have made meaningful criticisms of the status quo.
Dr Jones is an assistant professor in the Department of Psychiatry at the Morsani College of Medicine, University of South Florida and a faculty affiliate of the Louis de la Parte Florida Mental Health Institute. An applied mental health services researcher, her expertise includes the social and cultural determinants of pathways to and through care, early intervention in psychosis, multi-stakeholder perspectives on mental health services, and the relationship between poverty, education/employment and longer-term outcomes. She is currently a primary investigator or site PI on grants funded by the Patient Centered Outcomes Research Institute (PCORI), National Institute of Disability, Independent Living and Rehabilitation Research (NIDILRR) and the National Institute of Mental Health (NIMH).
Although I had known about Nev Jones, PhD, for some time and had interacted with her on social media, I remember the exact moment when I found myself in complete awe of her. It was when I read David Dobb’s article “The Touch of Madness,” a profile on her life and career.1 It remains one of the most remarkable and thought-provoking profiles I have read as a psychiatrist. The article describes her experiences of psychosis as a doctoral student in philosophy, the ways in which her social circle reacted, her encounters with the mental health system, the derailment of her career as an aspiring philosopher, and the beginning of her career as a brilliant psychologist, who has used insights from her own lived experience to shed light on the ways in which our current practices are failing those who need our help the most.
Aftab: Without repeating your life story, which can be gleaned in the Dobb’s article, how has your own experience with schizophrenia spectrum psychosis shaped your understanding of what psychosis is and of the role played by culture and stigma in shaping this experience and in determining the outcomes?
Jones: In general, I tend to situate my views on experience within the standpoint theory literature, broadly understood—ie, that knowledge, in general, is socially situated, and that an individual and collective identities and experiences shape (but, of course, do not simplistically determine) one’s understanding of world, self and others, one’s particular attunement to relations of power, what speakers and what conclusions one finds to be credible. All of us, of course, have our own sets of experiences and identities, some socially or structurally imposed, others that we ourselves explicitly take on.
Having made this general claim, when it comes to psychosis specifically—both the experience itself, and the clinical relationships in which one then finds oneself—a few things really stand out for me. One is a deep realization of (and then attunement to) the complexities of the experiences that fall under the psychosis umbrella—the many and variable forms they take, certainly, but above all their liminality. Not always, but a lot of the time. By that (liminality) I mean that, for many of us, language quickly breaks down, as do the psychological constructs and categories we tend to rely on. Although it could also be the case that the experience of psychosis really only exposes limits and fissures that are always already there, but masked.
In any case, I feel like there was an enormous disconnect between my experiences and the more mainstream conceptualization of psychosis (and key symptom categories—hallucinations, delusions, passivity phenomena, alogia). Not just because the assumed distinctions between delusion/belief and hallucination/sensation, say, or between thought and the spoken word, easily dissolve in actual experience, but also because of the ambiguous, indeterminate role of agency, our own agency, as we struggle to apprehend these limits. I will come back to this later in the interview.
The second key issue for me is power. Power both in the sense of “force” (physical and legal) as well as relational power as it circulates between people. We all deal with, and are constantly immersed in, relations of power, but as a patient navigating psychosis (and perhaps even more so, because of its social and clinical positionality, “schizophrenia”) we tend to experience this in particularly deep, generally subjugating, ways: eg through very strong forms of social rejection and exclusion, fear, misrecognition, assumed impairment, and disability. Then, at a more macro level, invisibility and devaluation when it comes to thinking about social justice, socioeconomic reform, and so on. If anything I have experienced this in a much more attenuated way than so many other people I know, or have subsequently met or worked with. As an interviewee in a study put it, “we’re throw away people.”
So that is at least a start. Both these areas—phenomenology and then power—are pretty clearly at the heart of my research.
Aftab: Starting with psychopathology, can you say more about your perspective on the unacknowledged complexities of psychosis/schizophrenia? What you describe in a published commentary2 as inadequately reflected in current textbook descriptions of psychosis?
Jones: Absolutely. I should start by emphasizing that psychosis is of course an umbrella term that includes an absolutely huge array of different alterations of experience, or alterations of patterns of experience. Yet we—and psychiatry and the allied psy-sciences—by and large do not engage with this breadth, depth, and variety at all. Philosophers of psychiatry love to refer to a 2006 article by Nancy Andreasen, MD, PhD—juicily titled “DSM and the Death of Phenomenology in America”—and I think it is actually worth quoting her analysis directly. One of the major problems she identifies is a very fundamental misunderstanding of what the DSM does, namely that:
"The criteria include only some characteristic symptoms of a given disorder. They were never intended to provide a comprehensive description. Rather, they were conceived of as ‘gatekeepers’—the minimum symptoms needed to make a diagnosis. Because DSM is often used as a primary textbook or the major diagnostic resource in many clinical and research settings, students typically do not know about other potentially important or interesting signs and symptoms that are not included in DSM."3
I would word this more strongly. Most clinicians I know have trained, interviewed, or otherwise interacted with have very explicitly been trained to view DSM symptom lists as comprehensive. A few indicators have, in essence, become the thing itself in working clinicians’ minds. The consequences of this, only some of which Andreasen herself describes, cannot be overstated. Misunderstanding, misrecognizing, reducing, and over-simplifying psychosis can and does impact everything from translational neuroimaging (dependent on the use of standardized measures) and new drug development, to clinical conceptualization and the capacity of clinicians to engage more deeply with clients. Clients who feel profoundly misunderstood may never open up in therapy or consultations.
Aftab: You have done some fascinating work on the phenomenology of psychosis. For instance, on the nature of auditory hallucinations4, on the role of agency and interpretation5, and sexuality6 in the phenomenology of psychosis. What are some of main findings and conclusions of this body of research?
Jones: After a very difficult period—and I suppose I should really stress that had you told the Nev of 2007 that she would be become a professor of psychiatry, she would have told you that you were completely out of your mind—I got into grad school (in psychology), started doing research, and also facilitating Hearing Voices Groups. As a patient earlier on, I think it is fair to say that I honestly was never very sure that I was experiencing psychosis/schizophrenia, precisely because it seemed to diverge so profoundly from, for example, the standard SCID questions. At least as I heard and understood them. But then, once I started to interact with other people, and not just a random few but a lot, through research, peer support and facilitation, eventually training and outreach, I began to realize “this is not just me at all.”
In fact, at multiple points, I felt heartbroken hearing other individual’s stories and the extent to which they felt they could not open up, had never even tried to describe so much of their experience to clinicians, or had long ago given up trying. Many of these were folks who had been in the public mental health system for decades; who had worked with dozens and dozens of different clinicians and social workers. The areas of misunderstanding or silencing or invisibilization took different forms, and I listened to this and really this is what informed my initial research.
Just as 1 example, I briefly mentioned the Hearing Voices Groups at a large service user gathering, and an older woman raised her hand and asked if I could talk to her after the meeting. “You said voices group,” she said, “can you say what you mean by that?” “Well,” I responded, “they take a huge variety of forms and voices is itself maybe not the greatest term. Some people literally hear a voice, for others it is more quasi-auditory, for others even a color with words jumbled in. For instance one of the members of my group refers to a group of her voices as a ‘wall of color’ that comes at her. Does this help?” I asked. At that point, she literally broke down crying and then proceeded to talk about the decades she spent thinking that, in spite of a diagnosis of schizophrenia, she did not really hear voices, she did not know what to call them, that something was wrong with her because even her schizophrenia was not real.
These experiences, as well as my own, inspired me and galvanized me to try and elevate these experiences and their complexities. So that is what I did—a series of qualitative publications on aspects of psychosis/schizophrenia that I felt had and have been extremely neglected or even dismissed and devalued.
Aftab: Looking at your publication history, it seems like you then moved away from phenomenology and, for the past 5 or 6 years, have mostly published research on mental health services. Would you say that these more recent studies and publications have more to do with what you referred to as relations of power?
Jones: Yes, precisely. I think I felt very strongly that I needed to do what I could to, as I say, complicate extant understandings of psychosis. Having tried my best to do that, I wanted to tackle the more macro issues of power, engagement and outcomes in services, and beyond that work designed to deepen our understanding of ways in which structures and institutions—welfare policy, income inequality, structural racism and xenophobia, for example—shape psychiatric discourse and the trajectories of those who end up in this space, especially on the severe end of the spectrum.
I would add that, as strange as it might sound, I see psychiatry and the mental health system as, in a sense, victims of (or at least profoundly constrained by) broader policy. Socioeconomics are much more central in my mind. Not just in the sense that structural disadvantage are profoundly implicated in the epidemiology of serious mental illness but also in the sense that what people are, and what they can do with their lives, is tied to socioeconomic capital, to income (in)security, and the central roles of work and productivity in the context of socially valued roles. From the perspective of social justice, certainly it is important to try to address problems at the level of psychopathology but also the extra-individual ways in which macro-level systems shape people lives and do so, when it comes to serious mental illness [SMI], in ways that are anything but just and equal. So, a lot of my more recent work has focused on the ways in which deeper structural disadvantage, poverty, the American benefits system and so on, influence what options are available, what services look like, and how lives unfold over the longer term.
Aftab: The inclusion of consumer/survivor/ex-patient (c/s/x) perspectives in academic discourse in psychiatry has historically been a very neglected area. What are some of the consequences and implications of this absence? I am interested in the way this exclusion has affected psychiatry but also how it has affected those who have been excluded. It is common for me to encounter service users on Twitter who have had unfavorable and negative experiences with psychiatric care, and many of them experienced that their voices were not heard, and resultantly there is a lot of anger, pain, and frustration, sometimes to a point that individuals have lost all trust in the medical system.
Jones: Certainly—and this is true across many different systems—criminal justice, child welfare, income-based social services, disability. At the broadest level the problem is really the problem of social hierarchies, hierarchies of marginalization and exclusion, and in some cases incarceration and harm. Historically, for example, forced sterilization, decades-long and sometimes life-long periods of (involuntary) commitment to asylums or state hospitals. There is collective pain, and also individual pain and distrust and anger. The tragedy here is that we have never seen the kind of dialogues and collaboration happen, at least on a large scale, that this history demands. That is, there seems to me so much potential for deep listening and systemic rethinking or redesign work. Where policy is the real barrier, collaboration to change policy. That this has not happened only further undermines trust in the system and helps seed ideological polarization. Since I am active both in user/survivor activist spaces as well as academic groups and lists, I often feel particularly painfully aware of the almost endless opportunities for dialogue, and the huge contribution that service users could make, but also the lack of meaningful opportunities to do so.
Aftab: Dobbs wrote in his article: “In the United States, the culture’s initial reaction to a person’s first psychotic episode, embedded most officially in a medical system that sees psychosis and schizophrenia as essentially biological, tends to cut the person off instantly from friends, social networks, work, and their sense of identity.”1
This is something I have observed as well in the context of inpatient psychiatric hospitalizations for first episode psychosis. Psychiatric hospitalization is often a practical necessity since we as a society have failed to invest in other methods of psychiatric crisis management, but I do recognize that it can be incredibly traumatic for some individuals (while being therapeutic for others). Psychiatric hospitals prioritize patient safety over comfort and autonomy, but an extreme emphasis on safety can sometimes be misplaced. The idea that we are fulfilling our duty to patients by offering them medications in a locked-door setting with bare-bones amenities reminds me of our attitudes towards children in the pre-attachment theory era when the consequences of maternal deprivation were seen as unimportant as long as the infant was physically cared for. Future generations may see our psychiatric hospitalization practices with a similar mix of curiosity and horror. What are your thoughts on this?
Jones: Involuntary hospitalization is something I have only recently started to study, although, as you say, it is an almost ubiquitous facet of pathways to and through early care for youth and young adults with first episode psychosis. A few years ago, I was awarded an internal grant to investigate the impact of involuntary hospitalization on youth (across the diagnostic spectrum), and we now have our first papers under review from the qualitative arm of this project. Overwhelmingly, within this sample, participants described inpatient environments as cold, dehumanizing, and punitive (with clearly negative impacts on participants’ reported willingness to trust future providers or disclose suicidal thoughts). Perusing this data, I think it is been the description of involuntary hospitalization as a kind of “punishment” that I found most striking and most thought-provoking. Increasingly the questions I have been asking myself, in part inspired by the “legal socialization” literature in criminology, concern the extent to which (and the ways in which) these experiential entanglements of force and treatment, as well as perceived moralization in the paradoxical context of otherwise biomedicalized care, in turn shape the development of system-related values, attitudes, and moral reasoning. I say paradoxical because one of the primary underlying motivations for physical health analogies has often been the putative mitigation of moral blame or culpability; and yet at the intersection of involuntary treatment and mental health, moral blame/moral discourse seemingly creeps right back in.
Of course, the existence and structuring of the average inpatient facility absolutely reflects the positionality and status of mental health challenges and crises in the United States. It is thus a kind of societal indictment. I also feel like this is pretty widely agreed upon. Few direct care clinicians I know are under any illusion about the therapeutic capacities of standard state or county-funded inpatient facilities.
Aftab: What do you think of the early intervention in psychosis (EIP) services as they currently exist? What are some things these services are doing right, and what are some of the areas in which they need to improve?
Jones: I think that if we compare average-to-good early intervention in psychosis services to status quo care the difference is stark. Meaning that so much of the time, under care as usual, the only service young people will actually have access to is medication management and maybe, if they are lucky, some access to a therapist with at least minimal training in psychosis. EIP services have also really helped to elevate the relative clinical standing of what, for decades in the United States, has been an incredibly neglected sub-group. That is not to say services are perfect, nor that implementation has not been uneven—some states, like New York have massively invested in training, technical assistance and support, whereas in other states EIP programs are under-funded and isolated, with little or no support. Because I do research on early psychosis around the country, this really manifests in interviews with young people from well-supported, high quality versus under-resourced, bare bones EIP services.
I would say that the real elephant in the room is what comes after early intervention—assuming access to well-implemented programs—what are young people with ongoing psychosis supposed to do following discharge? Here the broader issue of how society—including employers and institutions of higher education—view psychosis/schizophrenia also rears its head. Even under the best of circumstances, clinical interventions can only go so far, if societal structures and institutions do not accept (and ideally) embrace members of the broader community with disabilities and mental differences. Some of my teacher assistants work has tried to move in this direction—eg, with Substance Abuse and Mental Health Services Administration [SAMHSA] funding I developed 2 toolkits on supporting students with early psychosis in higher education, but we clearly have a long way to go.
Aftab: The role played by socioeconomic determinants—poverty, racial discrimination, stigmatization, domestic abuse, lack of education, unemployment etc—in influencing the risk and course of schizophrenia has received relatively scarce research attention, although things are beginning to change. While a biogenetic conceptualization of schizophrenia has certainly downplayed social and structural factors with regards to poor outcomes, what is interesting is that some of the critical discourse has also shown a neglect of social and structural factors, and has instead been focused on trying to tie the poor outcomes to the use of antipsychotic medications. What do you make of this situation?
Jones: As I see it there have always been threads within the broader user/survivor movement that have focused on medications and treatment as central targets to the neglect of underlying structural determinants. This line of inquiry has consumed so much oxygen that it has ended up contributing to a neglect of structural determinants. I regularly talk to people who, for example, bring up the patently false claim that it has been demonstrated that chronic psychosis would not exist were it not for antipsychotics. Ergo, this logic goes, all we have to do is remove medications from the equation and we would massively reduce disability, chronicity, and so on. Similar logics seem to operate for Open Dialogue—the belief, that is, that if we simply withhold or massively reduce antipsychotics early on, chronic psychosis will never develop.
What do I make of this all? It is frustrating in a whole lot of ways: the overwhelming focus on medications (or interventions like Soteria associated with the minimization of medication use) ends up providing an almost perfect alibi for the kinds of conservative social welfare and benefits policies in place in the United States since the mid-90s. Ultimately, what we are not then doing is coming together, across identity and coalitional lines, to think deeply and creatively about the vast array of crisscrossing structural determinants: income inequality, urban living conditions, limited class mobility, structural racism, and healthcare financing. Those are, from my perspective, the really major players here.
Aftab: Popular discourse on psychiatry, especially on online platforms and social media, is characterized by an extreme polarization. What do you think are some of the driving forces of this polarization, why should we be worried about it, and what can be done?
Jones: I often think that if we knew each other—as human beings rather than caricatured identity groups (whether service users, activists, or psychiatrists)—we would actually find a lot of common ground, or could. Build common ground, that is. Also, through dialogue, everyone learns to think more deeply, and with more nuance, about the issues at hand.
Another contributor, as I mentioned previously, is certainly individuals with various ideological axes to grind—a phenomena we find on both ends of the ideological spectrum. These polarizing figures almost invariably seem to have little to no investment in re-centering the views of those actually on the receiving end of public sector services, who, especially when it comes to schizophrenia/psychosis, are disproportionately poor, black, and subject to myriad forms of disadvantage. Again, when I was a grad student in Chicago, doing research in several of the city’s more notorious “service ghettoes,” I can tell you that the individuals I spoke to, interviewed, worked with for various projects, were not putting “decreased medication prescribing” on top of their priority list. It was housing, basic income, access to food. I remember going on a home visit with an ACT team I was working with to accompany a pregnant soon-to-be-young-mother to the grocery story, and just feeling heartbroken that, 5 months before her baby was due, she was trying to build up a supply of diapers so that she would have enough when the baby was actually born. When push comes to shove, there is not even the slightest doubt in my mind that addressing these kinds of social conditions—exemplified by the incredible poverty this young woman was experiencing, and the underlying social disinvestment in people with significant psychiatric disabilities it represents—is the real priority when it comes to justice.
Aftab: I would like to talk about the polarized state of online discourse on antipsychotics a little bit more. On the one hand we see folks insisting that everything is hunky-dory, and the very notion that the long-term use of antipsychotic medications could worsen functional outcomes even in some individuals is summarily dismissed. On the other hand, we see a sort of fanatic conviction that antipsychotics are toxic medications, that they in fact make schizophrenia worse, and the best thing we can do is to taper people off these medications. Based on my understanding of the literature, the notion that there is a subset of individuals in whom long-term use may worsen outcomes strikes me as a plausible hypothesis, albeit one that needs to be confirmed by future research in the form of randomized controlled trials (and may very well turn out to be true or false). What is clear is that people have very different experiences with these medications. For some these medications can be incredibly therapeutic, offering relief and functional restoration, but for others, these medications may not do much or may cause harms. What is your take on this issue and in your opinion what are some of the pitfalls?
Jones: I completely agree with you. I remember sitting in on a panel presentation with Lex Wunderink, MD, PhD, back in 2015 or so (Wunderink, for instance, has looked at long-term recovery rates in individuals with first-episode psychosis with antipsychotic dose reduction/discontinuation7); after the presentation a very senior and influential schizophrenia researcher in the United States described Wunderink’s work as extremely important, and made basically the same points you do above, but concluded that the big challenge is that we just do not know (and cannot currently identify) these sub-groups (people who will benefit, people who will not, in what ways and over what stretch of time). Obviously, this is not very helpful for either clients (or clinicians or family) stuck making decisions about medications in the here and now. Also, in general, I think people tend to find areas of high uncertainty (in any medical context) highly stressful and discomforting. What I do think we need a lot more of in this space is true information and decision aids—ie resources that lay out where the research literature is really at, that is transparent about the myriad unanswered questions we have, and that do not attempt to spin or sugar coat any of it. (I can honestly say I have never seen anything that I think actually does this—none of the medication-related shared decision-making tools or resources I know of, that is.)
Aftab: As a psychiatric researcher and as someone with lived experience, you are a success story of service-user involvement in mental health research. What are the challenges you have experienced in navigating this dual role, especially with regards to simultaneously existing in the vastly different cultures of the psychiatric research community and the c/s/x community? How hard is it to do interdisciplinary work in an environment driven almost entirely by National Institutes of Health [NIH] grants?
Jones: Honestly, I will not consider myself successful (at least by the standards of the academy) until I have an R01 Notice of Award in hand. Otherwise it is very challenging, quite painful a lot of the time—cognitive dissonance, code-switching. Back in 2017, the Alternatives conference, that big national gathering of user/survivor activists, happened to coincide in both time and place with the National Institute of Mental Health [NIMH] services conference. One of the days, I co-led a workshop on service user research involvement and priorities at Alternatives in the morning and presented at the NIMH venue in the afternoon. When I mentioned this to a handful of people at the latter, they had no idea the former was happening. I did not run into a single other university-based researcher at Alternatives. This is a kind of structural example of what I see a lot—the opportunities to come together, but simultaneously the degree of separation, the lack of awareness. For me, the challenges of always feeling, uncomfortably, caught between 2 worlds.
Right now, a group of colleagues and I have a commentary in press8 on ways in which the field (administrators, senior PIs, funders) could better support a pipeline of mental health services students, trainees, and researchers with experience of significant psychiatric disabilities and intersecting experiences of disadvantage. I would love for the research community to engage with and dialogue about the problems we call out and suggestions we raise there.
Aftab: How can psychiatry and psychology trainees acquire a better appreciation of the consumer/survivor/ex-patient perspectives? Is there any literature that you would like to recommend?
Jones: A big part of me wants to completely side-step this question because while there are many powerful first-person accounts and narratives out there, I think that what is really needed is not more reading but direct engagement, dialogue, conversation. Clinicians as well as virtually all translational, clinical and services researchers talk to service users all the time—however, this talk generally takes place in the form of the unidirectional provision of expert therapy or “management.” Instead, diverse service users need to be invited to the table as epistemic agents and interlocutors, rather than informants. All of us have to allow ourselves to be moved, emotionally as well as intellectually, in the course of this dialogue. We also need relationships, not one-off conversations, relationships that can grow and evolve over time.
For anyone who does not know where to start, I am—seriously—happy to make introductions, suggest listservs and forums where clinicians and researchers without existing relationships could start to make them. (My Twitter handle @viscidula.)
Aftab: Thank you!
The opinions expressed in the interviews are those of the participants and do not necessarily reflect the opinions of Psychiatric Times.
Dr Aftab is a psychiatrist in Cleveland, Ohio, and Clinical Assistant Professor of Psychiatry at Case Western Reserve University. He is a member of the executive council of Association for the Advancement of Philosophy and Psychiatry and has been actively involved in initiatives to educate psychiatrists and trainees on the intersection of philosophy and psychiatry. He is also a member of the Psychiatric Times Advisory Board. He can be reached at email@example.com or on twitter @awaisaftab.
Dr Aftab and Dr Jones have no relevant financial disclosures or conflicts of interest.
1. Dobbs D. The Touch of Madness. Pacific Standard. October 3, 2017. Updated November 26, 2018. Accessed September 20, 2020. https://psmag.com/magazine/the-touch-of-madness-mental-health-schizophrenia
2. Jones N, Shattell M. Not What the Textbooks Describe: Challenging Clinical Conventions About Psychosis. Issues Ment Health Nurs. 2016;37(10):769-772.
3. Andreasen NC. DSM and the death of phenomenology in America: an example of unintended consequences. Schizophr Bull. 2007;33(1):108-12.
4. Jones N, Luhrmann TM. Beyond the sensory: Findings from an in-depth analysis of the phenomenology of “auditory hallucinations” in schizophrenia. Psychosis. 2016;8(3):191-202.
5. Jones N, Shattell M, Kelly T, et al. “Did I push myself over the edge?”: Complications of agency in psychosis onset and development. Psychosis. 2016;8(4):324-35.
6. Jones N, Rosen C, Kamens S, Shattell M. “It was definitely a sexual kind of sensation”: sex, sexual identity, and gender in the phenomenology of psychosis. Psychosis. 2018;10(2):122-31.
7. Wunderink L, Nieboer RM, Wiersma D, et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913-20.
8. Jones N, Atterbury K, Byrne L, et al. Lived experience, research leadership and the transformation of mental health services: Building a pipeline. Psychiatric Services. In press.